Author: Emily Mallory

Breast cancer, a leading cause of cancer-related death, poses a significant health concern for women worldwide. Despite widespread screening efforts, over 42,000 women die each year from the disease. Early and accurate detection is critical, yet current imaging technologies often fall short, especially for women with dense breast tissue, where the current imaging technologies lack sensitivity. MALCOVA is a company dedicated to revolutionizing breast cancer screening by addressing the challenges posed by dense breast tissue. Founded in 2020 by Dr. Tara Ghazi and Dr. Peymon Ghazi, MALCOVA is a medical technology company headquartered in Newark, California. According to co-founder and…

More than 60% of women in the United States will experience incontinence at some point during their lives. Often presenting after childbirth, stress urinary incontinence is the leakage of urine during any activities that increase pressure in the abdominal cavity, like exercise, sneezing or coughing. Women experiencing urinary incontinence endure discomfort and embarrassment, significantly decreasing quality of life. The pelvic floor is a network of muscles that support all pelvic organs, including the bladder, bowel, and uterus. Sphincters within the pelvic floor contract to provide voluntary control over urination and defecation. Urinary incontinence is the involuntary leaking of urine often…

Biomarkers are measurable signs that provide objective information about what is happening inside the body, such as: heart rate, blood pressure, and certain lab tests. AOA Dx is a Massachusetts-based company that developed a platform to diagnose early-stage cancer through molecular biomarkers in the blood called gangliosides. Gangliosides are a type of lipid existing on the membrane of cells. Two specific gangliosides, GD2 and GD3, are uniquely expressed in certain types of tumor cells. When these gangliosides leak into the bloodstream they can be picked up by AOA’s GlycoLocate™ Platform technology after a routine blood draw. AOA’s GlycoLocate™ Platform plans…

An estimated 71.5 million U.S. adults use wearable devices to collect biometric data, a measurement of various physical characteristics. Wearable technology encompasses a variety of interactive devices that track user-specific data. Common gadgets include the Apple Watch, FitBit, and Aura Ring. These devices track biometric data while the device is worn to communicate information such as heart rate, oxygen saturation and temperature. This increasingly popular form of data collection allows people to make informed decisions about their health and wellness, and often assists healthcare providers with remote monitoring of chronic disease. Wearable technology is revolutionizing modern healthcare with its reliable…